PharmaCyte Biotech, Inc. PMCB
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) is an oncology drug developer. Its lead program, CypCaps (Cell-in-a-Box encapsulated cells with prodrug), is in Pre-clinical for locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). Its next catalyst on record is corporate (Nasdaq listing): Nasdaq minimum bid price compliance deadline; reverse split authorized if needed (November 30, 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: corporate (Nasdaq listing) — Nasdaq minimum bid price compliance deadline; reverse split authorized if needed (November 30, 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CypCaps (Cell-in-a-Box) | locally advanced pancreatic cancer (IND on clinical hold since Oct 2020) | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.